ClinicalTrials.gov record
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

ClinicalTrials.gov ID: NCT05253209

Public ClinicalTrials.gov record NCT05253209. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 12:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

Study identification

NCT ID
NCT05253209
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Enrollment
64 participants

Conditions and interventions

Interventions

  • L-citrulline Drug
  • Plasmalyte A Drug

Drug

Eligibility (public fields only)

Age range
Up to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 28, 2022
Primary completion
May 9, 2024
Completion
May 9, 2024
Last update posted
Sep 18, 2024

2022 – 2024

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Children's of Alabama Birmingham Alabama 35233
Children's Hospital of Colorado Aurora Colorado 80045
Heart Center, Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611-2605
Riley Hospital for Children at Indiana University Health Indianapolis Indiana 46202
Cardinal Glennon Children's Hospital St Louis Missouri 63104
Duke University Medical Center Surgical Office of Clinical Research (SOCR) Durham North Carolina 27710
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229
Nationwide Children's Hospital- The Heart Center Columbus Ohio 43215
Seattle Children's Research Institute Seattle Washington 98105
University of Wisconsin-Madison Madison Wisconsin 53792-4108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05253209, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 18, 2024 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05253209 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →